Pneumonia testing market seen reaching $4.63 billion by 2035

Market Research Future projects the global pneumonia testing market will grow from $2.44 billion in 2026 to $4.63 billion by 2035, driven by rising pneumonia cases, antimicrobial resistance and faster point-of-care molecular testing. The report also points to expanding reimbursement, hospital adoption and diagnostics investment across North America and Asia-Pacific.

Why it matters: - Pneumonia remains a major infectious-disease burden, and faster testing can help clinicians choose antibiotics sooner. - The market is expanding as health systems move away from slower culture-based methods and toward rapid molecular and antigen testing. - The shift affects hospitals, emergency departments, urgent care clinics and public health surveillance.

What happened: - Market Research Future said the global pneumonia testing market will rise to $4.63 billion by 2035 from $2.44 billion in 2026. - The firm put the market at $2.27 billion in 2025. - The forecast implies a 7.40% compound annual growth rate from 2026 through 2035. - The report was released July 14, 2026. - The company offered a free sample and a detailed report.

The details: - The report ties growth to pneumonia incidence, antimicrobial resistance and the spread of multiplex molecular panels. - The WHO estimates pneumonia kills more than 2.5 million people each year, including 700,000 children under five. - Antimicrobial-resistant Streptococcus pneumoniae strains now exceed 30% prevalence in multiple WHO regions. - Rapid point-of-care diagnostics are gaining ground in primary care and emergency settings. - The U.S. CMS issued new CPT reimbursement codes in 2024 for several FDA-cleared syndromic respiratory panels. - Emergency departments account for more than 40% of point-of-care respiratory test use in the U.S. - Molecular and antigen-based platforms now deliver results in about 15 to 45 minutes, versus 24 to 72 hours for conventional workflows. - The U.S. CDC’s Advanced Molecular Detection initiative has directed more than $170 million toward respiratory surveillance infrastructure. - Gavi has committed more than $1.5 billion to pneumococcal vaccine introduction in 60+ low-income countries. - The WHO Global Action Plan on AMR has helped drive national action plans in more than 140 countries. - Many of those plans require diagnostic testing before antibiotic prescribing in hospitals.

Between the lines: - The market is being shaped less by discretionary healthcare spending and more by structural demand for infectious-disease diagnostics. - Reimbursement changes matter because they make bedside molecular testing easier for hospitals to adopt. - Stewardship rules and AMR pressure are pushing clinicians and health systems toward broader use of syndromic panels. - The competitive edge appears to be moving toward broad-menu platforms that combine speed, low per-test cost and recurring consumable sales.

What's next: - Market Research Future expects consumables to remain the largest product segment, with analyzers the fastest-growing. - PCR is projected to stay the dominant technology, while molecular diagnostics remain the largest method type. - Hospitals are expected to remain the biggest end-user group, but diagnostic centers and decentralized point-of-care sites should keep gaining share. - North America is forecast to remain the largest regional market, while Asia-Pacific is expected to grow the fastest. - The report expects AI-enabled diagnostic workflows and microfluidic, lab-on-chip systems to expand use cases through 2035. - The company said AI-assisted diagnostics could cut inappropriate antibiotic prescribing by 25% to 30% in hospital settings by 2032.

The bottom line: - Pneumonia testing is shifting from a niche lab function to a core part of hospital triage, antimicrobial stewardship and respiratory surveillance. The fastest gains are likely to come from rapid molecular platforms, reimbursement support and expanding testing infrastructure in emerging markets.